Skip to content

A Study on the Correlation Between Endometriosis and Intra-tissue Microbiota

A Study on the Correlation Between Endometriosis and Intra-tissue Microbiota

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06266897
Enrollment
500
Registered
2024-02-20
Start date
2023-06-18
Completion date
2026-12-31
Last updated
2024-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometriosis

Keywords

Microbiota, Microbiome, Endometriosis

Brief summary

Endometriosis (EM) is a common gynecological condition, but the pathogenesis of it has not yet been clarified. Here, the investigators wanted to investigate the correlation between endometriosis and the intra-tissue microbiota. The investigators planed to collect serum, vaginal swabs, cervical mucus, feces, peritoneal fluid, and endometrial tissue for sequencing and experiments.

Detailed description

Endometriosis (EM) is a common gynecological condition that occurs in women of reproductive age and is characterized by pain, masses, and infertility. EM is a tumor-like disease that is invasive, metastatic, recurrent, but the pathogenesis of EM has not yet been clarified. Advances in the study of intratumoral microbiota provided increasing evidence confirming the presence and mechanism of bacteria in tumor tissues. Therefore, the investigators wanted to investigate the correlation between endometriosis and its microbiota in the endometrial tissue. Participants in this study will be recruited in the obstetrics and Obstetrics and Gynecology Medical Center of Zhujiang Hospital. With reference to the inclusion and exclusion criteria, patients admitted for surgery were under screening. Participants were assigned to Endometriosis group after confirmation by laparoscopy together with biopsy analysis, while the control group was identified as non-EM patients, usually with benign gynecologic conditions such as uterine fibroids or teratomas. The investigators will obtain serum, vaginal swabs, cervical mucus, and feces from the participant before surgery. The peritoneal fluid, eutopic endometrium, and ectopic endometrium lesion will also be collected if the surgical approach allows. The specimens will be sent for microbiota sequencing, transcriptome sequencing, metabolome sequencing, single cell sequencing, and laboratory experiments.

Interventions

None listed

Sponsors

Zhujiang Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 52 Years
Healthy volunteers
Yes

Inclusion criteria

1. Women aged 18-52 years old. 2. Regular menstruation with a cycle of 28-35 days. 3. No sexual intercourse 1 week before the operation. 4. No systemic or local use of antibiotics and probiotics for 6 months prior to surgery. 5. No history of acute or chronic pelvic inflammatory disease. 6. Subjects fully understand the significance of the study and sign the informed consent form.

Exclusion criteria

1. In pregnancy. 2. Intraoperative conditions or pathological examination suggest a malignant or junctional disease. 3. Severe anatomical abnormalities of the pelvis. 4. Pelvic contamination with large amounts of blood during laparoscopic operation. 5. History of gene therapy, blood transfusion, stem cell therapy, or bone marrow transplantation 6. Psychiatric, personality disorders, or abuse of psychoactive substances. 7. Immunodeficiencies, allergies, or autoimmune diseases. 8. Contraindications to endotracheal intubation anesthesia. 9. Absolute or relative contraindications to laparoscopic or hysteroscopic surgery.

Design outcomes

Primary

MeasureTime frameDescription
Metagenomics Next Generation Sequencing of the Intra-tissue Microbiota Composition3 yearsUsing metagenomics sequencing of microbiota, compare the microbial composition differences of specimens derived from EM group and control group, including the alpha diversity(Shannon index, Simpson index, etc.), beta diversity(PCoA analysis, Bray-Curtis, etc.) differential taxonomy, and KEGG pathway prediction.

Countries

China

Contacts

Primary ContactZiwei Zhou, Dr
vivienchow@qq.com+8615626400134
Backup ContactYuying Chen, Dr
2265991412@qq.com+8618218058905

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026